Distribution (GDP)4 min read

Belgian and Dutch wholesale distribution authorisations compared: what is the same and what differs

A company with premises in both countries deals with two authorities and two applications, but one inspection standard. This guide sets out what the two systems share, where they differ and what that means in practice.

MEDCORRegulatory and quality consultancy led by Hendrik Staels

Published Also available inNederlands

ShareLinkedInWhatsAppEmail

A wholesale distribution authorisation (WDA) is granted by one country's authority for premises on that country's territory. A company that distributes medicines from both Belgium and the Netherlands therefore has two authorisations, two applications and two authorities to deal with. What it is inspected against is the same in both: the EU Good Distribution Practice (GDP) Guidelines.

The short answer

  • Same standard. Both countries inspect against the EU GDP Guidelines (2013/C 343/01) (opens in a new tab) and require a named Responsible Person and a working quality system.
  • Different authority and route. In Belgium the FAMHP grants the authorisation. In the Netherlands the application goes through Farmatec, with the IGJ (the Dutch Health and Youth Care Inspectorate) advising and supervising.
  • Different national rules. The legal basis, the forms and some national roles differ. The Responsible Person for Information and Publicity (RIP), for example, is a Belgian role.

What is the same

The legal frame comes from EU law: Directive 2001/83/EC (opens in a new tab) requires an authorisation to act as a wholesaler of medicines, tied to the premises in the country that grants it. Beyond that, the two systems rest on the same building blocks:

  • The EU GDP Guidelines set the quality system, premises, documentation, transport and complaints expectations, and section 2.2 sets out the responsibilities of the Responsible Person.
  • The authorisation names the activities and the site, and the company's activities have to stay within them.
  • Inspections follow the chapters of the GDP Guidelines, and GDP certificates are published in the EudraGMDP database (opens in a new tab).

Where they differ

TopicBelgiumNetherlands
Who grants and supervisesThe FAMHP (opens in a new tab) (FAGG in Dutch, AFMPS in French)Application through Farmatec (opens in a new tab), with advice and supervision from the IGJ (opens in a new tab)
Main legal basisArticle 12ter of the Medicines Act of 25 March 1964 and Articles 90 to 99 of the Royal Decree of 14 December 2006 (opens in a new tab) (Dutch)The Geneesmiddelenwet (Dutch Medicines Act), chapter 3, with its implementing rules
Responsible PersonNamed in the application, under Belgian eligibility, presence and notification rulesNamed in the application, with the IGJ's published GDP questions and answers describing what it expects
Responsible Person for Information and Publicity (RIP)A Belgian role linked to medicines information and advertisingNot a Dutch role
Language of the processForms and guidance in Dutch, French and, in part, EnglishForms and guidance in Dutch

What this means in practice

  • Plan one application per country. Each names its own Responsible Person and its own premises.
  • Keep one quality system, with local evidence. A group procedure can serve both countries, but each authority will want to see it applied at the premises it covers.
  • Do not carry roles across the border. A Belgian RIP does not exist in the Dutch system, and a Responsible Person is appointed for a specific authorisation.
  • Check the source for the authority you are dealing with. Forms and requirements are updated on the FAMHP, Farmatec and IGJ sites.

Where MEDCOR can help

For Belgian authorisations we prepare applications and changes, build GDP quality systems and can act as the named Responsible Person or as RIP. For Dutch wholesale authorisations our offer is the named Responsible Person appointment. See our pages on the Responsible Person for a Belgian WDA and the Responsible Person for a Dutch WDA, or send us the outline of your project.

ShareLinkedInWhatsAppEmail
MEDCORRegulatory and quality consultancy led by Hendrik StaelsMEDCOR is the independent regulatory affairs and quality assurance consultancy of Hendrik Staels, industrial pharmacist. This guide was prepared by MEDCOR from the official sources cited in the text.
About MEDCOR

Information as at 21 November 2026. Rules, forms, fees and deadlines can change, so check the cited sources before you act. This guide is general information, not legal advice.

Distributing in Belgium, the Netherlands or both?

Tell us your scope and timing. We will say what is needed and where we can help.

Discuss your authorisation